The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Emerging Targets in Type 2 Diabetes and Diabetic Complications
Open accessAbstract
Type 2 diabetes is a metabolic, chronic disorder characterized by insulin resistance and elevated blood glucose levels. Although a large drug portfolio exists to keep the blood glucose levels under control, these medications are not without side effects. More importantly, once diagnosed diabetes is rarely reversible. Dysfunctions in the kidney, retina, cardiovascular system, neurons, and liver represent the common complications of diabetes, which again lack effective therapies that can reverse organ injury. Overall, the molecular mechanisms of how type 2 diabetes develops and leads to irreparable organ damage remain elusive. This review particularly focuses on novel targets that may play role in pathogenesis of type 2 diabetes. Further research on these targets may eventually pave the way to novel therapies for the treatment—or even the prevention—of type 2 diabetes along with its complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–216 of 216
Liu, Z., Zhang, Y., Qiu, C., Zhu, H., Pan, S., Jia, H., Kang, H., Guan, G., Hui, R., Zhu, L., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12789 · Cited by 29
Dai, W., Miller, W. P., Toro, A. L., Black, A. J., Dierschke, S. K., Feehan, R. P., Kimball, S. R., & Dennis, M. D. (2018) · The FASEB Journal · doi:10.1096/fj.201800413rr · Cited by 28
Insulin receptor substrate 1 is a substrate of the Pim protein kinases
Song, J. H., Padi, S. K. R., Luevano, L. A., Minden, M. D., DeAngelo, D. J., Hardiman, G., Ball, L. E., Warfel, N. A., & Kraft, A. S. (2016) · Oncotarget · doi:10.18632/oncotarget.7918 · Cited by 27
Modulation of Obesity and Insulin Resistance by the Redox Enzyme and Adaptor Protein p66Shc
Ciciliot, S., & Fadini, G. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040985 · Cited by 27
The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
Cherney, D. Z. I., Perkins, B. A., Lytvyn, Y., Heerspink, H. J. L., Rodríguez-Ortiz, M. E., & Mischak, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186910 · Cited by 26
Evaluation of Notch3 Deficiency in Diabetes-Induced Pericyte Loss in the Retina
Liu, H., Zhang, W., & Lilly, B. (2018) · Journal of Vascular Research · doi:10.1159/000493151 · Cited by 26
Impact of activating transcription factor 4 signaling on lipogenesis in HepG2 cells
Ren, L., Yu, X., Song, G., Zhang, P., Sun, L., Chen, S., Hu, Z., & Zhang, X. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5453 · Cited by 22
Edick, A. M., Auclair, O., & Burgos, S. A. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00025.2019 · Cited by 21
Shc depletion stimulates brown fat activity in vivo and in vitro
Tomilov, A. A., Bettaieb, A., Kim, K., Sahdeo, S., Tomilova, N. B., Lam, A., Hagopian, K., Connell, M. C., Fong, J., Rowland, D. J., et al. (2014) · Aging Cell · doi:10.1111/acel.12267 · Cited by 19
Koziczak‐Holbro, M., Rigel, D. F., Dumotier, B. M., Sykes, D. A., Tsao, J., Nguyen, N., Bösch, J., Jourdain, M., Flotte, L., Adachi, Y., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255307 · Cited by 19
Hagopian, K., Tomilov, A. A., Kim, K., Cortopassi, G. A., & Ramsey, J. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124204 · Cited by 17
Schwarz, D. F., Hidmark, Å. S., Sturm, V. J. F., Fischer, M. D., Milford, D., Haußer, I., Sahm, F., Breckwoldt, M. O., Agarwal, N. K., Kuner, R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64585-1 · Cited by 17
Self-citationShc proteins influence the activities of enzymes involved in fatty acid oxidation and ketogenesis
Hagopian, K., Tomilov, A. A., Tomilova, N. B., Kim, K., Taylor, S. L., Lam, A., Cortopassi, G. A., McDonald, R. B., & Ramsey, J. J. (2012) · Metabolism · doi:10.1016/j.metabol.2012.05.007 · Cited by 14
Involvement of advanced glycation end‐products in ‘hyperglycemic memory’
Nishikawa, T., & Araki, E. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12405 · Cited by 10
Xie, J., Shao, Y., Liu, J., Cui, M., Xiao, X., Gong, J.-B., Xue, B., Zhang, Q., Hu, X., & Duan, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-77096-w · Cited by 3
Coca, S. G., Ismail-Beigi, F., Haq, N., Krumholz, H. M., & Parikh, C. R. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.2230 · Cited by 1
Cited by
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Antar, S. A., Ashour, N. A., Sharaky, M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115734 · Cited by 622
Specific Nanodrug for Diabetic Chronic Wounds Based on Antioxidase-Mimicking MOF-818 Nanozymes
Chao, D., Dong, Q., Yu, Z., Qi, D., Li, M., Xu, L., Liu, L., Fang, Y., & Dong, S. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c09663 · Cited by 317
Tegegne, B. A., Adugna, A., Yenet, A., Yihunie Belay, W., Yibeltal, Y., Dagne, A., Hibstu Teffera, Z., Amare, G. A., Abebaw, D., Tewabe, H., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1440456 · Cited by 61
“There was a signi fi cant knowledge gap that has to be fi lled regarding the neurological, hepatic, ophthalmic, or renal issues related to DM (39, 40).”
Background
Metadata
- Authors
- Demir, S., Nawroth, P. P., Herzig, S., & Ekim Üstünel, B.
- Venue
- Advanced Science
- Publisher
- Wiley
- Published
- 2021-07-28
- Volume
- 8
- Issue
- 18
- Pages
- e2100275-e2100275
- ISSN
- 2198-3844 (ISSN-L)
- OpenAlex
- W3183548861
- Cited by
- 525
- References
- 216
- FWCI
- 45.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.